Welcome to our dedicated page for ACM Research SEC filings (Ticker: ACMR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ACM Research's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ACM Research's regulatory disclosures and financial reporting.
Wang David H reported acquisition or exercise transactions in this Form 4 filing.
ACM Research, Inc. reported an insider equity award connected to director and officer David H. Wang. A trust for his daughter, Sophia Wang, received a grant of 6,208 restricted stock units tied to Class A common stock. Each restricted stock unit represents a contingent right to receive one share of ACMR common stock, with the grant value based on a 30-day lookback average fair market value of $51.54 per share. These units vest in four equal annual installments beginning on May 13, 2027. The filing also lists indirect holdings of Class A common stock by several family-related trusts and by Wang’s spouse and daughter.
ACM Research, Inc. furnished an 8-K sharing a June 2026 investor Q&A from its listed subsidiary ACM Research (Shanghai), Inc. The Record notes that newly signed orders at ACM Shanghai rose 65% year-over-year in the first quarter of 2026 and that full-year 2026 revenue guidance is maintained at RMB 8.20–8.80 billion.
Management highlights strong demand for cleaning and electroplating tools, with electroplating systems representing about 30% of newly signed orders year-to-date. They describe how the Lingang mini-line is accelerating R&D, process validation and customer qualification, supporting faster adoption of new products such as PECVD and furnace systems.
The Q&A also outlines a long-term revenue target of USD 4 billion, split between USD 1.6 billion from overseas markets and USD 2.4 billion from mainland China, and indicates that once both Lingang Plants A and B are fully operational, combined annual output value is expected to reach roughly RMB 20 billion.
ACM Research, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. Holders of Class A and Class B shares representing 135,814,497 votes, or 84.32% of total voting power, were present in person or by proxy, establishing a strong quorum.
Stockholders elected four directors to serve until the 2027 annual meeting: David H. Wang, Haiping Dun, Tracy Liu, and Charles Pappis. Each nominee received over 117 million votes "for," with broker non-votes reported separately.
Stockholders also ratified the appointment of Ernst & Young Hua Ming LLP as independent auditor for the fiscal year ending December 31, 2026, with 135,717,653 votes for, 40,635 against, and 56,209 abstaining.
ACM Research, Inc. insider activity: Officer Cheav Sotheara reported exercising stock options for 18,750 shares of Class A Common Stock at an exercise price of $13.89 per share and selling 18,750 shares in open-market transactions on June 4–5, 2026.
The sales were executed at reported prices generally in the low-to-mid $80s per share across multiple trades and were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 5, 2026. Following these transactions, Sotheara directly holds 100,002 shares of ACM Research Class A Common Stock.
ACM Research, Inc. director and officer David H. Wang reported a mix of open-market sales and option exercises in Class A common stock. On June 3–4, he sold a total of 100,002 shares in multiple open-market transactions, including sales of 1,187 shares at $93.04 and 2,060 shares at $83.86 per share.
Over the same two days, Wang exercised stock options to acquire 100,002 shares of Class A common stock at a $1.00 per share exercise price, with the options fully vested and exercisable. Following these transactions, he holds 802,708 Class A shares directly, along with several indirect positions through family trusts and related accounts. The filing notes that the sales were made under a Rule 10b5-1 trading plan adopted on November 29, 2024, indicating the trades were pre-scheduled rather than discretionary.
ACMR notices a proposed sale of Common Stock via a Form 144 filing. The excerpt lists a Stock Option Exercise with an entry of 5,399 shares dated 06/05/2026 and a reported sale of 13,351 shares on 06/04/2026 for $1,136,821.63.
ACMR filed a Rule 144 notice reporting recent dispositions of Common Stock and a related option exercise. The filing lists three past sales by Hui Wang: 60,000 shares on 06/03/2026, 50,000 shares on 03/12/2026, and 60,000 shares on 03/11/2026 with dollar amounts shown. It also lists a stock option exercise on 06/04/2026 for 40,002 shares classified as ISSUER and paid in cash.
ACMR reports a proposed sale of 60,000 common shares under Rule 144. The filing lists 06/03/2026 as the sale date and identifies Morgan Stanley Smith Barney LLC Executive Financial Services as the broker. The method is described as a Stock Option Exercise with Cash settlement. The excerpt also shows prior sales by Hui Wang of 50,000 shares on 03/12/2026 for $2,278,825.00 and 60,000 shares on 03/11/2026 for $2,875,386.00.
ACM Research, Inc. reports that its operating subsidiary ACM Research (Shanghai), Inc. has board approval to pursue an H share offering and listing on the Main Board of the Hong Kong Stock Exchange. ACM Shanghai plans to issue H shares representing no more than 7% of its total issued share capital upon completion of the offering, with an over-allotment option of up to 15% of the initial H shares.
The H shares will be ordinary shares with a par value of RMB 1.00, offered through a Hong Kong public offering and international placing. Net proceeds are intended for product development, strengthening research and development, expanding global market and service capabilities, general working capital, and repayment of bank loans.
The plan, along with extensive related governance and structural changes, has been unanimously approved by ACM Shanghai’s board but remains subject to shareholder approval and multiple regulatory filings and clearances in mainland China and Hong Kong. The resolution for the H share listing would be valid for 24 months from shareholder approval, with automatic extension until completion of the listing and any over-allotment exercise if approvals are obtained within that period.